{"id":"mal-vehicle-cream","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vehicle cream, this formulation serves as the delivery system or base for active pharmaceutical agents rather than being a drug with its own mechanism of action. The cream base facilitates penetration and absorption of incorporated active ingredients through the stratum corneum and into deeper skin layers. The specific therapeutic mechanism depends on the active pharmaceutical ingredient combined with this vehicle.","oneSentence":"MAL Vehicle Cream is a topical formulation vehicle designed to deliver active pharmaceutical ingredients through the skin for localized therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:39.717Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Topical delivery vehicle for dermatological applications (specific indication dependent on active ingredient formulated with this vehicle)"}]},"trialDetails":[{"nctId":"NCT04269395","phase":"PHASE3","title":"A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study","status":"TERMINATED","sponsor":"Galderma R&D","startDate":"2020-04-07","conditions":"Keratosis, Actinic","enrollment":125},{"nctId":"NCT04085367","phase":"PHASE3","title":"Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2019-09-30","conditions":"Actinic Keratoses","enrollment":557},{"nctId":"NCT02799069","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy","status":"COMPLETED","sponsor":"Biofrontera Bioscience GmbH","startDate":"2008-04","conditions":"Actinic Keratosis","enrollment":571},{"nctId":"NCT02139618","phase":"PHASE2","title":"Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage","status":"COMPLETED","sponsor":"Fundación Dermabase","startDate":"2014-04","conditions":"Facial Photodamage","enrollment":60},{"nctId":"NCT00933543","phase":"PHASE2","title":"Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)","status":"COMPLETED","sponsor":"Photocure","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":107},{"nctId":"NCT00673933","phase":"PHASE2","title":"Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris","status":"COMPLETED","sponsor":"Photocure","startDate":"2008-05","conditions":"Acne Vulgaris","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MAL Vehicle Cream","genericName":"MAL Vehicle Cream","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MAL Vehicle Cream is a topical formulation vehicle designed to deliver active pharmaceutical ingredients through the skin for localized therapeutic effect. Used for Topical delivery vehicle for dermatological applications (specific indication dependent on active ingredient formulated with this vehicle).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}